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AKTIVITI ANTIPROLIFERATIF EKSTRAK DEBUNGA LEBAH 
KELULUT KEATAS KANSER PAYUDARA MCF-7 
 
ABSTRAK 
 
Tujuan kajian ini adalah untuk menentukan aktiviti antioksidan dan antiproliferatif 
daripada ekstrak debunga lebah kelulut spesis L. terminata. Aktiviti antioksidan 
ditentukan menggunakan 2,2-diphenyl-2-picrylhydrazyl (DPPH), dan Folin-Ciocalteu 
telah digunakan untuk menguji jumlah kandungan fenolik dalam ekstrak debunga lebah. 
3-[4,5-dimethylthiazol-2-YL] -2,5-diphenyltetrazolium (MTT) telah digunakan untuk 
menentukan aktiviti antiproliferatif. Kepekatan efektif (EC50) ekstrak debunga kelulut 
adalah 0.36mg/ml. Jumlah ekstrak fenolik pada 20mg /ml ekstrak debunga lebah adalah 
34.93±0.150mg/g. MTT menunjukkan ekstrak debunga lebah mempunyai kepekatan 
perencat (IC50) 25.5mg/ml bagi sel normal L929 manakala IC50 untuk sel kanser 
payudara MCF-7 adalah 15mg/ml, kajian ini menunjukkan bahawa ekstrak debunga 
lebah mempunyai kesan sitotoksik dalam sel-sel kanser, tetapi tidak dalam sel-sel 
normal. Gabungan cisplatin dan ekstrak debunga lebah menunjukkan interaksi sinergi 
dalam mendorong aktiviti pembunuhan sel kanser payudara MCF-7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
ANTIPROLIFERATIVE ACTIVITY OF STINGLESS BEE POLLEN 
EXTRACT ON HUMAN BREAST CANCER CELL LINE MCF-7 
 
 
ABSTRACT 
 
 
 
The aims of this study were to determine the antioxidant and antiproliferative activity of 
the bee pollen extract from stingless bee L. terminata. Antioxidant activity was 
determined using 2,2-diphenyl-2-picrylhydrazyl (DPPH), and Folin-Ciocalteu assays 
was used to test the total phenolic content in the bee pollen extract, the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT) assay was used to determine 
antiproliferative. The effective dose (EC50) of bee pollen extract was 0.36 mg/ml. Total 
phenolic content of bee pollen extract at 20mg/ml of bee pollen extract was 34.93 ± 
0.150mg/g.The MTT assay showed that bee pollen extract median inhibitory 
concentration (IC50) 25.5mg/ml for normal cell line L929 while IC50 for breast cancer 
cell MCF7 was 15mg/ml, this study indicates that bee pollen extracts have cytotoxic 
effect in cancer cells, but not in normal cells. The combination of cisplatin and bee 
pollen extract showed synergistic interaction in inducing the killing activity of breast 
cancer cell line MCF7. 
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 CHAPTER 1: INTRODUCTION 
 
 
 
Cancer is known as malignant tumor which this multifactorial cell disease involved 
abnormal cellular proliferation (Neve et al., 2006). The development of cancer cell 
depends on various changes of genetic and epigenetic in the cell (Giri et al., 2006), 
uncontrollable proliferation and lack of apoptosis event (Weaver and Cleveland, 2005). 
The development of cancer usually due to the imbalance expression of oncogenes, 
tumor suppressor gene and the alteration of the microRNA (Yanaihara et al., 2006). 
Treatment and cure of cancer problem was scientifically challenging and gave a serious 
burden on public health system which claim nine million lives worldwide by 2015 
(Rajesh et al., 2011). In Malaysia, cancer was established as the fourth main cause of 
death after cardiovascular disease (Lim, 2002). The death from breast cancer was 
reported by The Ministry of Health Malaysia to be rank among the top 10 cancer-related 
deaths in the country (Yip et al., 2006). As the cancer becomes one of the life 
threatening diseases throughout the world, there are interest to develop a new anticancer 
drugs, which are more specific and less side effects than chemotherapeutic drugs. 
Anticancer drugs have distinct mechanisms of action which may vary in their effects on 
different types of normal and cancer cell (Pascoal et al., 2014). There was plenty of 
antineoplastic agents that widely used for treatment of malignant cancer, but these 
anticancer drugs exhibit genotoxic and cytotoxic effect which inhibits the growth 
(Sánchez-Suárez et al., 2008). Presently, about 65% of the nature based 
chemotherapeutic drugs were established and have a long history in both traditional and 
modern cancer treatments (Conforti et al., 2008). 
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The relationship between bees, flowers and man is one of the wonders of the universe, 
being a living proof that the flora, fauna and man were made to live in harmony. Bees 
need flowers to feed themselves, plants need bees to be pollinated and to produce seed 
to ensure the perpetuation of plant species (Almeida-Muradian et al., 2005; Pascoal et 
al., 2014). Bee pollen was originated from the agglutination of flower pollens with 
nectar and salivary substances of the bees. Bee pollen is known and used since ancient 
times (Pratsinis et al., 2010; Kustiawan et al., 2014). Bee pollen is also the only perfect 
and complete food (Almeida-Muradian et al., 2005). It consists of polyphenol 
substances that are very useful in traditional and conventional medicine (Kustiawan et 
al.). Polyphenol known to help reduce the risk of severe diseases and cancer due to its 
antioxidant, antimutagenic, anti-inflammatory, antibacterial and anticancer activity 
(Jaganathan and Mandal, 2009; Pratsinis et al., 2010; Kustiawan et al., 2014; Pascoal et 
al., 2014). Thus, it is possible that bee pollen can serve as potential sources for 
developing new drugs and more effective anti-cancer agents for future therapy (Wu and 
Lou, 2007). 
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OBJECTIVES : 
 
 
• To study the antioxidant activity of stingless bee pollen extract.  
 
 
• To study the antiproliferative activity of bee pollen extract on human breast 
cancer cell line MCF-7  
 
• To explore the combination effect of bee pollen extract and anticancer drug 
cisplastin [cis-diammine-dichloroplatinum (II)] on breast cancer cell line  
(MCF-7)  
 
 
 
 
 
 
 
HYPOTHESIS: 
 
 
 
Bee pollen extract with good antioxidant activity has antiproliferative activity towards 
human breast cancer cell line (MCF-7), and its anti-proliferative activity exhibits a 
synergistic effect with anticancer drug cisplastin [cis-diammine-dichloroplatinum (II)]. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Breast cancer  
 
2.1.1 Prevalence and risk factor 
 
The breast is made up of glands lobules that produced milk and consists of thin tubes 
ducts that transported the milk from the lobules to the nipple. Breast tissue contains fat 
and connective tissue, lymph nodes, and blood vessels. Mammary carcinoma, the most 
common type of breast cancer is ductal carcinoma, which primarily developed in the 
cells of the ducts (Yip et al., 2006). Breast cancer proliferates in the cells of the lobules 
and metastasizes into the tissues in the breast. Invasive breast cancer is cancer that has 
spread from where it began in the ducts or lobules to surrounding tissue (Hisham and 
Yip, 2004). National Cancer Registry of Malaysia in 2006 reported that breast cancer 
one of the most diagnosed cancer among Malaysian women, which about 30.4 % cases 
reported without regard age and ethnicity (Yip et al., 2006). Different type of cancer 
showed different risk factors such as improper diet, genetic potentiality, and 
surrounding environmental factors (Are and Shaha, 2006). Breast cancer usually caused 
by single or combination of external and internal factors such as age and female sex as 
at the age of woman between 35 to 39 years showed higher rate of incidence (Lim, 
2002). Breast cancer also a type of cancer which interrelated with the cumulative 
lifetime exposure of estrogen hormone in the body, and this was one of the reason why 
the chances of women getting breast cancer was higher than men (Vona-Davis and 
Rose, 2009). About 5-10% breast cancer are due to genetic inheritance (Synowiec et al., 
2008). Other factor that related to the risk of breast cancer included high 
mammographic breast density, the used of exogenous hormones such as therapy that 
involved with hormone replacement, oral contraceptives, obesity and the 
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consumption of alcohol in daily life (Dumitrescu and Cotarla, 2005;Synowiec et al., 
 
2008). 
 
2.1.2 Breast cancer classification and treatment  
 
Breast cancer are categorized into different subgroup according to the  
 
histological type of the grade of tumor, the stage, lymph node status and molecular 
profile (Dumitrescu and Cotarla, 2005). The diagnosis and the treatment of breast 
cancer became more challenging when it involved the heterogeneity of the breast cancer 
(Saltz et al., 2008;Holliday and Speirs, 2011). There were few options for breast cancer 
such as surgery, chemotherapy, radiotherapy and hormonal therapy), however most of 
the treatment was very high in cost and at the same time gave adverse effect to the 
patient which also cause the resistance of cancerous cell towards the treatment (Alwan, 
2011). 
 
2.2 Chemotherapeutic agents  
 
 
Chemotherapy is known to be one of the most acceptable treatments worldwide. 
Chemotherapeutic agents were varied in their target and effectively kill most of the 
cancer cells. It can be considered as effective treatments in endocrine-responsive 
disease, however less effective for endocrine unresponsive tumors (Shaked et al., 2008). 
There are many types of strong potential chemotherapeutic agents that provided many 
different ways of killing the cancerous cell had been developed (Risques et al., 2011). 
However, chemotherapeutic agents alone sometime doesn’t give an increment in cure 
rates of cancer cells (HemaIswarya and Doble, 2006; Hemaiswarya et al., 2008). 
Chemotherapeutic treatment can cause side effects which can be divided into short-term 
and long term effects. Short term effects usually occurs during the period of treatment 
and the therapy will complete within a month, while the long term effect occurred post 
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treatment and long lasting for many years (Burstein et al., 2001). Examples of some 
side effects listed in table 2.1. 
 
Table 2.1 : List of reported short term and long term effects of chemotherapeutic 
agent (Esserman et al., 2001) 
 
 
 Short term effect  Long term effect 
    
- Emesis - Premature Menopause 
- Nausea - Weight gain 
- Stomatitis - Cardiac dysfunction 
- Myalgias - Leukemia 
- Hot flashes - Cataracts 
- Neuropathy -   Vascular related thrombotic events 
- Fatigue -   Development of another cancer 
- Myelosuppression   
- Thromboembolism   
- Myelosuppresion   
- Alopecia   
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More than 90% of patient with metastatic cancer was accounted for the failure of the 
treatment due to the resistance of cancer cell toward chemotherapeutic agent, as 
chemotherapeutic agent was not sensitive to cancer cell (Longley and Johnston, 2005). 
Chemotherapeutic resistance could happen due to internal exposure which known to be 
intrinsic resistance, and external exposure which was extrinsic resistance (Scotto, 2003). 
The resistance of cancer cell toward chemotherapeutic drugs due to a number of 
mechanism of cancer cell resistance such as defects in DNA repair pathway, 
suppression of cell death pathway, exclusion or active export of drug from the cell and 
regulation of epigenetic (Dingli and Michor, 2006). 
 
2.2.1 Cisplatin (cis-diamminedichloroplatinum(II)) (CDDP)  
 
Cisplatin is a chemodrug that interrupt the growth of cancer cells and inhibit  
 
their growth from spread throughout body. This antineoplastic agent was widely used to 
treat malignant solid tumor including testicular, ovarian, breast, lung, neck, head, 
bladder cancer (Aebi et al., 1996). Cisplatin is an effective antitumor medicine that 
often combined with other cancer drugs (Abdella et al., 2009). The type and extent of a 
cancer determines how effectively this medicine slows or stops the growth of cancer 
cells in the body. Majority of antineoplastic drug has generic growth property, display 
genotoxicity, and cytotoxic effect which could inhibit the growth of the cancer cell, but 
the toxic effect of the drug could also lead to initiation of unrelated tumor (Abdella et 
al., 2009). Cisplastin also has severe toxic effect which inhibit the therapeutic efficacy 
such as bone marrow toxicity, neurotoxicity, nephrotoxicity, hepatotoxicity after 
undergo chemotherapy (Arany et al., 2004; Chandrasekar et al., 2006; Abdella et al., 
2009). Cisplatin required dose administration and restriction for it optimal activity in 
cancer chemotherapy (Arany et al., 2004). 
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2.3 Natural products as a drug  
 
 
 
A chemical compound or substances that formed by living organism that showed 
biological and pharmacology activities are defined as natural products (S Gollahon et 
al., 2011). About 70% to 80% of herbal products are an essential source of medicine 
(Organization, 2002). Although there was development in anticancer drug, the natural 
source products still remained as products. Natural product was affordable and at the 
same time they are finer in term of safety and efficacy compared to synthetic products 
with less side effects (Johnston et al., 2006; Demain and Sanchez, 2009). Unfortunately, 
some of the natural products proclaimed for their advantage in traditional used were not 
scientifically proven for efficacy and adverse effects (Koehn and Carter, 2005). Natural 
products that had biological and pharmacology activities usually make them vital 
sources for drug discovery (Cragg et al., 1997). Around year 2000-2005 there were 
about 23 new drugs were identified from natural sources which can act as an ailment to 
various diseases such as cancer, cardiovascular, metabolic diseases and many others 
(Koehn and Carter, 2005; S Gollahon et al., 2011). 
 
Malaysia was known to be one of the countries that have variety natural 
products from tropical rainforest. The abundance of natural sources in Malaysia give 
many potential to researchers to develop medicinal products and into commercial 
market, at the same time coordinate research and development activities on medicinal 
plants was set up and formed in 1994 by The Malaysian Natural Products Society 
(Muhammad and Awaisu, 2008) to further promote our natural products. Over than 
1300 species of natural sources that comes from tropical rainforest of Malaysia showed 
medicinal properties such as Catharanthus roseus, which showed ability to become an 
anticancer drug and propolis from stingless bee, which showed antiproliferative activity 
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on human cancer cell lines (Chandrasekar et al., 2006). Whereas, anticancer activity of 
of Strobilanthes crispus known as “Pecah Beling”were seen on human breast and 
prostate cancer cells in vitro (Yaacob et al., 2010; Mohamad et al., 2011). 
 
 
2.4 Natural product as adjuvant therapy  
 
 
 
The effects of natural product in combination with anticancer drugs was 
investigated for their potential in improving the killing effects of multidrug resistance 
cancerous cell, and at the same time can overcome the toxicity effect against normal cell 
(Da Rocha et al., 2001; Butler, 2004). Some compounds in natural product showed a 
great combination effects which may work synergistically or antagonistically with the 
therapeutic activity of drugs (Hemaiswarya et al., 2008). For example, curcumin have 
antiproliferative effects in combination with doxorobucin in treating breast cancer cell 
(Hosseinzadeh et al., 2011) and at the same time, curcumin also give a great effect of 
antitumor and apoptotic activities of cisplatin against ovarian cell (Chan et al., 2003). 
Another example of component that derived from natural sources is genistein which 
worked synergistically with tamoxifen against breast cancer (HemaIswarya and Doble, 
2006). Oriental herbal medicines also showed anti-tumor effect and showed potential to 
overcome the side effect to normal cell (Kang et al., 2006). For example 
Bojungbangdocktang known as a Korean herbal medicine has ability to protect non-
cancerous epithelial cells of the breast (MCF10A) against apoptosis and cytotoxicity 
induced by cisplatin (Kang et al., 2006) and improved the anticancer effect of cisplatin 
against breast cancer cell MCF-7 (Fan et al., 1995). 
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2.5 Bee pollen  
 
 
2.5.1 Definition and characteristics of stingless bee pollen  
 
Bee pollen known as a pollen ball from the male seed of flower that gathered  
 
and packed by worker of stingless bees into pellets then transfer them back to colony by 
attached at their corbiculae (hind leg) of the bees (Almeida-Muradian et al., 2005). Bee 
pollen is a combination with plant nectar and bee saliva which contain its own digestive 
enzyme secretion from the hypopharyngeal glands, such as α and β-glycosidase 
enzymes (Tavdidishvili et al., 2014). Bee pollen also known to be the primary source of 
protein in the bee hive as the bees consumes as their own diets and at the same time they 
fed their own larvae. (Carpes et al., 2007). This meliponiculture product is known as 
product that are gathered and stored in honeycomb and covered the pollen with honey 
(Leja et al., 2007). Bee pollen was rich in minerals, simple sugars, proteins, vitamins, 
fatty acid, flavonoids, phenolic acid, carotenoids, phytosterols and other phytochemicals 
that responsible for showing the antioxidants activity of the bee pollen (Silva et al., 
2006). The composition of the bee pollen might vary depending on the floral, 
geographical area of the bee pollen, the season and method used to collect the bee 
pollen, as well as storage of the bee pollen after harvested (Cook et al., 2003; Campos et 
al., 2008). These factors might also affect the physical properties of the bee pollen such 
as color, shape, quantity. Hence, most of the reported bee pollen showed different 
medicinal properties (Carpes et al., 2007). 
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2.5.2 Benefits of bee pollen  
 
Bee pollen known to be used as a source of energy and nutrients for human to  
 
consume (Serra Bonvehi and Escolà Jordà, 1997). Bee pollen known worldwide for its 
used for dietary purpose and food supplement and has the ability to serve several 
pharmacological effects. However at the moment, there was not enough evidence to 
support on the relationship between chemical constituents with its pharmacological 
effects (Mason, 2012). Bee pollen also categorized under nutraceuticals and therapeutic 
food that provides nutrients to reduce the potential in developing certain illness. This is 
because bee pollen has very high in amino acids and at the same time also is high in 
various vitamins and minerals, such as calcium and lysine, as well as phosphorus. 
Lysine has a potential to absorb calcium, which proven that potential for bone health 
and it can help with the formation of bone callus that is associated with fractures 
(Hayden, 1980). It is also help to improve the bone health which is very suitable for the 
brittle bones (Yamaguchi et al., 2006). Bee pollen also beneficial in preventing 
osteoporosis (Hamamoto et al., 2006). 
 
 
The therapeutic properties of bee pollen include anti-inflammatory, antibacterial, 
antifungal, wound healing, cytotoxicity effect, immune booster and at the same time 
stimulate the tissue regeneration (Šarić et al., 2009). It is also been used for treatment of 
acute and chronic free radical-mediated diseases such as artherosclerosis, diabetes and 
cancer (Wu and Lou, 2007). The therapeutic properties of bee pollen able to overcome 
multi-factorial causes of carcinogenesis such as free radicals, chronic infection, 
inflammation and low immune status (Medeiros et al., 2008). 
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Several studies shown that bee pollen had a great potential to sustain antioxidant 
capacity due to high content of phenolic acids and flavonoid content (Kustiawan et al., 
2014). Recent findings also proven that bee pollen of stingless bee showed cytotoxity 
effect toward human cancer cell line including ductal carcinoma, lung undifferentiated 
cancer, liver hepatoblastoma, and breast cancer (Chantarudee et al., 2012; Kustiawan et 
al., 2014). The increasing data collected on stingless bee pollen for medicinal and 
therapeutic purposes led to the resurgence of interest in stingless bee pollen. 
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CHAPTER 3: MATERIALS AND METHODS 
 
 
3.1 Sample collection  
 
 
 
Bee pollen was harvested from the stingless bee hive located at Tasek Gelugor, 
Penang. Bee pollen sample was from the species L. terminata, which was identified by 
Entomology unit, MARDI, Serdang. Harvested bee pollen was then dried at 40℃ for a 
week before kept in +4℃ fridge until further used. 
 
3.2 Extraction of bee pollen  
 
 
 
This method was modified from (Kustiawan et al., 2014).Ten grams of bee 
pollen sample was weighed and put into 50ml Falcon tube. Twenty five millilitre of 
methanol was added. Three different concentrations of methanol (70%, 80% and 100%) 
were used for bee pollen extraction. The mixture of bee pollen with methanol was then 
vortexed for 10 minutes, and sonicated for 1 hour in 4℃ . The bee pollen mixture was 
then kept overnight at +4℃ . 
 
The mixture was then centrifuge at 6000 rpm for 10 minutes and the supernatant 
was transferred into the clean falcon tube. The remaining precipitate was discarded. 
These processes were repeated until the supernatant become clear. The supernatant was 
then filtered using 0.2µm sterile filter unit (Millipore, USA). The supernatant was dried 
in rotary evaporator at 40℃ and freeze dried for one week. After one week the sample 
was weighed again and kept in -20℃ until further use. The percentage of extraction 
efficiency was calculated using formula: 
 
 % extraction efficiency = ( Mo / M  ) x 100 
* Mo: weight of freeze dried bee pollen extract,   Weight of bee pollen before extract 
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3.3 2,2-Diphenyl-1-picrylhydrazyl (DPPH) antioxidant activity of bee 
pollen extract 
 
 
 
This method was modified from (Kustiawan et al., 2014). The stock solution of 
2,2-Diphenyl-1-picrylhydrazyl (DPPH) was prepared using 12mg of DPPH powder 
(Sigma Aldrich, USA) with 50ml of methanol in dark. Trolox (6-Hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid) (Sigma Aldrich, USA) was used as standard to 
generate standard curve with concentration 25µM, 169µM, 313µM, 475µM, and 
600μM. About 7.5µl of trolox from each concentration was pipetted with 150µl of 
270 μM DPPH. Absorbance was read using microplate reader (BMG Labtech, 
Germany) at 517nm after 30 minutes. The bee pollen samples stock were prepared by 
diluting 0.1g of bee pollen extract with 1ml of methanol and diluted into concentrations 
of 2.5mg/ml, 5mg/ml, 10mg/ml, 15mg/ml, and 20mg/ml. About 7.5µl of bee pollen 
extract from each concentration was mixed with 150µl of 270µM DPPH, and the 
mixture’s absorbance was read using microplate reader. For the negative control, 
methanol without BPE was used. (Kustiawan et al., 2014). DPPH free radical 
scavenging activity was calculated using the following formula: 
 
 
 
 
 
% scavenging = [Absorbance of control - Absorbance of test sample/Absorbance of 
control] X 100 
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3.4 Total phenolic content of bee pollen extract  
 
 
 
This method was modified from (Chan et al., 2008).The phenolic content of bee 
pollen extracted was tested with different concentrations which were 2.5mg/ml, 5mg/ml, 
10mg/ml, 15mg/ml, and 20mg/ml. Folin-Ciocalteau solution was prepared by adding 
2.5ml Folin-Ciocalteau reagent with 25ml distilled water. Sodium carbonate solution 
was prepared using 1.5g of sodium carbonate powder mixed with 20ml distilled water. 
About 12µl of bee pollen extract from each concentration was mixed with the freshly 
prepared 60µl Folin-Ciocalteau solution, then left for 10 minutes and the mixture was 
resuspended. Then, 48µl sodium carbonate was added and the mixture resuspended at 
37℃ for 30 minutes. The absorbance was read at 760nm. Gallic acid was used as 
standard in this experiment. Gallic acid stock was prepared 20µM and diluted with 
concentrations of 0.125mM, 1.25mM, 2.5mM, 5mM, 10mM, and 20mM were used to 
construct a calibration curve. Distilled water was used for negative control. All samples 
and control were prepared triplicates. The total phenolic content of the samples were 
analysed based on the measured absorbance, the concentration of phenolics was read in 
(mg/ml) from the calibration curveline, the total phenolic content the bee pollen extracts 
was expressed in the terms of gallic acid equivalent (mg of GA/g of extract). 
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3.5 Cell culture  
 
3.5.1 Maintenance of cell lines 
 
Two types of cell lines were used in this study which were normal mouse fibroblast cell 
L929 and breast cancer epithelial cell MCF-7. 
 
3.5.2 Reagents for cell culture 
 
The reagents used in this study were Dulbecco’s modified Eagle Medium (DMEM) 
 
(Gibco BRL, UK)   for   MCF-7 and  L929, FBS  (100ml)  (Gibco   BRL, UK) 
 
penicillin/streptomycin solution 10mg/ml (Gibco BRL, UK) 1X phosphate buffered 
saline (Gibco BRL,UK) and Trypsin 0.25%, EDTA 0.03% (Gibco BRL, UK). All 
reagents were thawed and aliquot into small sterile tubes and kept -20℃ until further 
used. 
 
3.5.2 (a) Medium 
 
 
One type of media reagents used in this study was Dulbecco’s Modified Eagle Medium 
(DMEM) ( Gibco BRL,UK) for MCF-7 and L929 cells. 
 
3.5.2 (b)Heat inactivated Foetal Bovine Serum (FBS) 
 
 
A bottle of readymade FBS (100ml) (Gibco BRL,UK) was heat inactivated by placing it 
 
in water bath at 56℃ for 30 minutes. The serum was then aliquoted into sterile 15ml 
 
Falcon tubes and kept at -20℃ for further used. 
 
 
3.5.2(c) Penicillin/ Streptomycin stock solution 
 
A bottle of ready-made penicillin/streptomycin solution 10mg/ml (Gibco BRL, UK) 
was thawed and aliquoted into sterile 5ml eppendorf tube and kept -20℃. 
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3.5.2(d) 1x Phosphate Buffered Saline (PBS) 
 
 
A bottle of ready-made 11X phosphate buffered saline (Gibco BRL,UK) and was 
aliquoted 50ml in falcon tube and kept in 4℃ for further used. 
 
3.5.2(e) Trypsin 0.25%, EDTA 0.03 % 
 
 
Ready-made Trypsin 0.25%, EDTA 0.03% (Gibco BRL, UK). All reagents were 
thawed and aliquot into small sterile tubes sterile 15ml tubes and kept -20℃ for further 
used. 
 
3.5.2(f) Complete growth medium for MCF-7 and L929 cells 
 
 
MCF-7  and  L929  was  cultured  and  maintained  at  37℃ in  5%  CO2  humidified 
 
atmosphere in DMEM medium supplemented with 5% FBS and 1% antibiotic 
(penicillin/streptomycin). 
 
3.5.2(g) Cryopectant Medium 
 
 
 
MCF-7 and L929 cells were cryopreserve in 10% dimethyl sulphoxide (DMSO) in the 
cryotube and stored in -80℃ for further used. 
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3.5.3 Cultures procedures and conditions 
 
All the procedures were carried out inside the class II Biohazard Cabinet and handled 
with proper aseptic technique to avoid contamination. Good cell practice guidelines 
were practiced throughout this study. 
 
3.5.3(a) Retrieving of cells from frozen storage 
 
 
A cryovial containing frozen cells was retrieved from -80℃ freezer and left at room 
 
temperature for about 5 minutes to thaw the cells. Thawed cells were then transferred 
into a sterile 15ml falcon tube containing pre-warmed growth medium. It was then 
centrifuge at 1000rpm for 5 minutes. The supernatant was discarded and 1ml of PBS 
was added, before centrifuged again at 1000rpm for 5 minutes. This procedure was done 
to reassure the complete removal of cryopectant medium from the cells. The supernatant 
was discarded and the cell pellet was resuspended in 1ml growth medium. The cell 
suspension was divided into two 25cm2 culture flasks, containing 5ml of DMEM. The 
flasks were then incubated in the 5% CO2 incubator at 37℃ to allow the attachment of  
 
cells. 
 
 
3.5.3(b) Sub-culturing of cells 
 
 
When the cell reached 80% confluence the cells were passaged. The process was done 
by removing the medium from the flask and rinsed with 2ml of PBS. The PBS was 
discarded followed by addition 1ml of Trypsin-EDTA solution into the 75cm2 cell 
culture flask, and left in the 5% CO2 incubator for 5 minutes for the cell to detach. The 
flask was gently shaken to make sure the cell was fully detached, and then the flask was 
observed under the inverted microscope. Three milliliter of fresh medium was added to 
the flask together with the trypsin, and then transferred into the centrifuge tube. The 
tube was then centrifuged at 1000rpm for 5 minutes. The supernatant was removed and 
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pellet was resuspended with 1ml medium and divided into three new flasks. About 7ml 
 
of fresh medium was added to each 75cm2 and the flask was incubated. 
 
 
3.5.3(c) Determination of cell number for seeding 
 
3.5.3(ci) Trypan blue 0.1%(w/v) solution for cell counting 
 
 
The solution (10ml) was prepared by diluting 2.5ml of readymade 0.4 %( w/v) Trypan 
blue (Gibco BRL, UK) in 7.5ml PBS and kept at room temperature until use. About 
10µl of cell suspension was added with 90µl of Trypan blue solution. The mixture was 
resuspended in 1.5ml eppendorf tube. Then 10µl of the mixture was pipetted onto the 
haemocytometer (Figure 3.1) and observed under inverted microscope. The number of 
viable cell estimated as below: 
 
 
 
 
 
Number of viable cells/ml = 
n x dilution factor x 104
4
 
 
 
n = Total number of stained cell in 4 grid 
 
 
 
The number cell that counted for seeding in 96 well plate was 1x104  
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Figure 3.1: Illustration of haemacytometer 
 
 
The numbered area are the area which cell were counted under inverted microscope 
 
 
http://a.static-abcam.com/CmsMedia/Media/haemocytometerdiagramv3.jpg 
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3.6 Preparation of bee pollen extract  
 
 
The stock solution of bee pollen extract was freshly prepared by diluting 0.1g of 
bee pollen extracts with 1ml DMEM with the final concentration of 100mg/ml, and then 
filtered using 0.2µl sterile filter unit (Millipore,USA). Stock solution was further diluted 
to desire concentration (2.5mg/ml, 5mg/ml, 10mg/ml, 20mg/ml and 40mg/ml). 
 
3.6 Preparation of cisplatin  
 
 
The stock solution of 10mM cisplatin was prepared by dissolving 6mg of 
cisplatin (Trevigen,USA) (MW= 300.01 g/mol) with 2ml DMEM. The solution was 
well mixed and aliquoted into several sterile microcentrifuge tubes and stored at -20℃ . 
The working solutions of the drug were freshly prepared in assay medium for prior 
usage. 
 
3.7 Cytotoxicity determination using MTT assay  
 
 
The Vybrant® MTT Cell Proliferation Assay Kit (Thermo Fisher Scientific, 
USA) was used to determine the anti-proliferative effect of cisplatin and bee pollen 
extract, as a single agent or in combination treatment on L929 and MCF-7 cells. MTT 
assessing cell metabolic activity of NAD(P)H-dependent cellular oxidoreductase 
enzymes, in which under defined conditions reflect the number of viable cells. 
NAD(P)H-dependent oxidoreductase enzymes largely present in the cytosolic 
compartment of the cell. 
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3.7.1 Treatment controls 
 
 
The following controls were prepared in each experimented setup in order to calculate 
the percentage of anti-proliferative activity of bee pollen extract and cisplastin: 
 
a)  Background/blank control 
 
One well contained 200µl of assay medium alone or DMSO 
 
 
b) Negative control  
 
Control well contained untreated cells.  
 
 
3.7.2 Treatment of cell using MTT assay  
 
 
3.7.2(a) Treatment with bee pollen extract and cisplatin alone 
 
 
Cells were harvested and counted as described in 3.5.3(c) and seeded about 1 x 104 cells 
in 96 wells plate. The plate was incubated overnight in the incubator with humidified 
atmosphere containing 5% CO2 at 37℃. After incubated overnight the growth medium 
was carefully removed when the cell reached 80% confluence. Then 200µl of freshly 
prepared assay medium containing different concentration bee pollen extract which 
were (2.5mg/ml, 5mg/ml, 10mg/ml, 20mg/ml and 40mg/ml). Similarly for cisplastin 
treatment, the cells were treated with different concentrations of cisplatin at 2.5 µM, 
5µM, 10µM, 15µM, 20µM, 30µM, 40µM and 50µM. Each experiment was done in 
triplicate. Once treated, the 96 well plate was incubated for 48 hours. 
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3.7.2(b) Treatment with bee pollen extract in combination with cisplatin 
 
 
Cells were harvested, counted before being seeded in 96 wells plate as described in 
3.5.3(c). The stock culture was counted for 1X104 cells/ml then seeded 200µl triplicate, 
for bee pollen extract drug combination with cisplatin in 96 well plate. The plate then 
incubated with humidified atmosphere containing 5% CO2 at 37℃. When the cell 
reached 80% confluence, the growth medium was carefully removed. For combination 
treatment about 200µl fresh prepared medium containing with (2.5µM, 5µM, 10µM, 
15µM, and 20µM) with constant concentration of 15mg/ml bee pollen extract. Once 
treated, the 96 well plate was incubated for 48 hours. Each experiment was done in 
triplicate. The data from of drug combination was analysed using Compusyn software to 
determine the synergistic, additive and antagonistic effect of these 2 drugs combination. 
 
3.7.2(c) Preparation of MTT assay reaction mixture 
 
 
Twelve millimolar MTT stock solution was prepared by adding 1mL of sterile PBS to 
5mg of MTT. The mixture was mixed by vortexing or sonicating until it dissolved. The 
medium which contain L929 or MCF-7 cells was then removed and replaced with 100 
µL of fresh culture medium. 10µL of the 12mM MTT stock solution was added to each 
well, and then the cells was incubated at 37°C for 4 hours. After labeling the cells with 
MTT, the medium was removed but with only 25µL of medium left from the wells. 
About fifty microliter of DMSO (Sigma Aldrich, USA) was added to each well and 
mixed thoroughly with the pipette. The plate was incubated at 37°C for 10 minutes and 
the absorbance was read at 540 nm. The percentage of cell proliferation was calculated 
using formula below: 
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The percentage of cell proliferation was calculated using formula below: 
 
 
 
 
% cell proliferation =  x 100   
 
 
 
 
 
 
 
 
3.8 Statistical analysis  
 
 
 
All value was expressed as the mean + standard deviation of triplicate analyses. Due to 
the sample size was <30, all statistical analysis in this study was determined using non 
parametric independent T test using IBM SPSS statistics version 18 (IBM Inc, USA). 
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Absorbance sample - Absorbance blank 
Absorbance negative – Absorbance blank 
